Company profile for Oxeia Biopharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE-103, beginning a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients. The U.S. Centers for Disease Control and Prevention estimates that ...
Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapeutics for mild traumatic brain injury (mTBI), known as concussion, and related neuro-metabolic dysfunction. The company has a drug, OXE-103, beginning a Phase 2 clinical trial in the fall of 2020. To date there are few other studies aimed at treating these patients. The U.S. Centers for Disease Control and Prevention estimates that just under three million concussion cases visit U.S. emergency rooms annually. Other studies put the number much higher at five million, with as many as 2.4 million of these with mTBI.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
9920 Pacific Heights Blvd., Suite 150 San Diego, CA 92121-4361
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/08/03/2491668/0/en/OXEIA-ANNOUNCES-POSITIVE-INTERIM-RESULTS-OF-PHASE-2-TRIAL-FOR-OXE103-FOR-THE-TREATMENT-OF-CONCUSSIONS.html

GLOBENEWSWIRE
03 Aug 2022

https://www.prnewswire.com/news-releases/oxeia-biopharmaceuticals-announces-new-board-and-management-team-members-and-relocates-corporate-headquarters-to-boston-301464807.html

PRNEWSWIRE
20 Jan 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty